HRP20021032B1 - NOVEL SOLID BODY FORMS OF MESOPROGESTIN 11C-[4E-(HYDROXYIMINOMETHYL)-PHENYL]-17α-METHOXYMETHYL-17C-METHOXY-ESTRA-4,9-DIEN-3-ONE - Google Patents

NOVEL SOLID BODY FORMS OF MESOPROGESTIN 11C-[4E-(HYDROXYIMINOMETHYL)-PHENYL]-17α-METHOXYMETHYL-17C-METHOXY-ESTRA-4,9-DIEN-3-ONE

Info

Publication number
HRP20021032B1
HRP20021032B1 HR20021032A HRP20021032A HRP20021032B1 HR P20021032 B1 HRP20021032 B1 HR P20021032B1 HR 20021032 A HR20021032 A HR 20021032A HR P20021032 A HRP20021032 A HR P20021032A HR P20021032 B1 HRP20021032 B1 HR P20021032B1
Authority
HR
Croatia
Prior art keywords
hydroxyiminomethyl
estra
dien
methoxymethyl
methoxy
Prior art date
Application number
HR20021032A
Other languages
English (en)
Croatian (hr)
Inventor
Grawe Detlef
Hoesel Peter
Mueller Uwe
Winter Gabriele
Original Assignee
Bayer Schering Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Aktiengesellschaft filed Critical Bayer Schering Pharma Aktiengesellschaft
Publication of HRP20021032A2 publication Critical patent/HRP20021032A2/hr
Publication of HRP20021032B1 publication Critical patent/HRP20021032B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36Antigestagens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR20021032A 2000-05-23 2002-12-23 NOVEL SOLID BODY FORMS OF MESOPROGESTIN 11C-[4E-(HYDROXYIMINOMETHYL)-PHENYL]-17α-METHOXYMETHYL-17C-METHOXY-ESTRA-4,9-DIEN-3-ONE HRP20021032B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00110887A EP1157996A1 (de) 2000-05-23 2000-05-23 Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
PCT/EP2001/005237 WO2001090137A2 (de) 2000-05-23 2001-05-09 NEUE FESTKÖRPERFORMEN DES MESOPROGESTINS 11β-[4E-(HYDROXYIMINOMETHYL)-PHENYL]-17α-METHOXYMETHYL-17β-METHOXY-ESTRA-4,9-DIEN-3-ON

Publications (2)

Publication Number Publication Date
HRP20021032A2 HRP20021032A2 (en) 2005-02-28
HRP20021032B1 true HRP20021032B1 (en) 2008-09-30

Family

ID=8168805

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20021032A HRP20021032B1 (en) 2000-05-23 2002-12-23 NOVEL SOLID BODY FORMS OF MESOPROGESTIN 11C-[4E-(HYDROXYIMINOMETHYL)-PHENYL]-17α-METHOXYMETHYL-17C-METHOXY-ESTRA-4,9-DIEN-3-ONE
HR20080423A HRP20080423A2 (en) 2000-05-23 2008-08-29 NOVEL SOLID BODY FORMS OF MESOPROGESTIN 11C-[4E-(HYDROXYIMINOMETHYL)-PHENYL]-17α-METHOXYMETYL-17C-METHOXI-ESTRA-4,9-DIEN-3-ONE

Family Applications After (1)

Application Number Title Priority Date Filing Date
HR20080423A HRP20080423A2 (en) 2000-05-23 2008-08-29 NOVEL SOLID BODY FORMS OF MESOPROGESTIN 11C-[4E-(HYDROXYIMINOMETHYL)-PHENYL]-17α-METHOXYMETYL-17C-METHOXI-ESTRA-4,9-DIEN-3-ONE

Country Status (30)

Country Link
US (1) US7799770B2 (cs)
EP (3) EP1157996A1 (cs)
JP (1) JP2003534350A (cs)
KR (1) KR100553292B1 (cs)
CN (1) CN100384867C (cs)
AT (1) ATE397617T1 (cs)
AU (2) AU2001256344B2 (cs)
BG (1) BG65968B1 (cs)
BR (1) BR0111058A (cs)
CA (1) CA2409869C (cs)
CZ (1) CZ2003620A3 (cs)
DE (1) DE50114012D1 (cs)
DK (1) DK1292607T3 (cs)
EA (1) EA005623B1 (cs)
EC (2) ECSP024358A (cs)
ES (1) ES2307613T3 (cs)
HR (2) HRP20021032B1 (cs)
HU (1) HUP0301956A3 (cs)
IL (2) IL152868A0 (cs)
ME (1) MEP15608A (cs)
MX (1) MXPA02011524A (cs)
NO (1) NO327004B1 (cs)
NZ (1) NZ522768A (cs)
PL (1) PL358789A1 (cs)
PT (1) PT1292607E (cs)
RS (1) RS50493B (cs)
SK (1) SK2922003A3 (cs)
UA (1) UA73988C2 (cs)
WO (1) WO2001090137A2 (cs)
ZA (1) ZA200209322B (cs)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
WO2006078731A2 (en) * 2005-01-18 2006-07-27 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Amorphous and crystalline forms of dorzolamide hydrochloride and processes of making same
US20090054387A1 (en) 2006-04-18 2009-02-26 Detlef Grawe Method for preparing 4-[17beta-methoxy-17alpha-methoxymethyl-3-oxestra-4,9-dien-11beta-yl]benzaldehyde (E)-oxime (asoprisnil)
DE102006018888A1 (de) * 2006-04-18 2007-10-25 Bayer Schering Pharma Ag Verfahren zur Herstellung von 4-[17beta-Methoxy-17alpha-methoxymethyl-3-oxoestra-4,9-dien-11beta-yl]benzaldehyd-(E)-oxims (Asoprisnil)
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19610667C2 (de) * 1996-03-08 1998-04-09 Schering Ag (Z)-11ß-[4-(Dimethylamino)phenyl]17ß-hydroxy-17alpha-(3-hydroxy-1-propenyl)estr-4-en-3-on als kristallines Ansolvat
EP1204656A2 (en) * 1999-07-29 2002-05-15 Eli Lilly And Company A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene hydrochloride

Also Published As

Publication number Publication date
ZA200209322B (en) 2005-03-10
ECSP084358A (es) 2008-11-27
EP1862469A2 (de) 2007-12-05
NO20025613D0 (no) 2002-11-22
CA2409869C (en) 2009-02-03
HUP0301956A2 (hu) 2003-09-29
DK1292607T3 (da) 2008-10-13
NZ522768A (en) 2005-03-24
PL358789A1 (en) 2004-08-23
BG65968B1 (bg) 2010-07-30
JP2003534350A (ja) 2003-11-18
EA200201192A1 (ru) 2003-06-26
AU2001256344B8 (en) 2001-12-03
CA2409869A1 (en) 2002-11-20
HUP0301956A3 (en) 2010-03-29
AU5634401A (en) 2001-12-03
ECSP024358A (es) 2003-03-31
MEP15608A (en) 2010-06-10
SK2922003A3 (en) 2003-08-05
MXPA02011524A (es) 2004-09-10
US20040006241A1 (en) 2004-01-08
KR100553292B1 (ko) 2006-02-22
ATE397617T1 (de) 2008-06-15
UA73988C2 (en) 2005-10-17
YU88702A (sh) 2006-01-16
IL152868A (en) 2009-08-03
ES2307613T3 (es) 2008-12-01
CN100384867C (zh) 2008-04-30
DE50114012D1 (en) 2008-07-17
WO2001090137A2 (de) 2001-11-29
CN1430624A (zh) 2003-07-16
CZ2003620A3 (cs) 2003-08-13
EP1157996A1 (de) 2001-11-28
WO2001090137A3 (de) 2002-04-04
IL152868A0 (en) 2003-06-24
PT1292607E (pt) 2008-09-15
EP1292607B1 (de) 2008-06-04
NO20025613L (no) 2002-11-22
AU2001256344B2 (en) 2007-01-25
BG107557A (bg) 2004-01-30
RS50493B (sr) 2010-03-02
EP1292607A2 (de) 2003-03-19
BR0111058A (pt) 2003-04-15
EA005623B1 (ru) 2005-04-28
HRP20080423A2 (en) 2008-10-31
US7799770B2 (en) 2010-09-21
HRP20021032A2 (en) 2005-02-28
NO327004B1 (no) 2009-04-06
KR20030028742A (ko) 2003-04-10

Similar Documents

Publication Publication Date Title
HRP20021032B1 (en) NOVEL SOLID BODY FORMS OF MESOPROGESTIN 11C-[4E-(HYDROXYIMINOMETHYL)-PHENYL]-17α-METHOXYMETHYL-17C-METHOXY-ESTRA-4,9-DIEN-3-ONE
GB0102797D0 (en) Crystalline base of citalopram
HK1070000A1 (en) Crystalline composition containing escitalopram
DE60112974D1 (en) Carbolinderivate
HK1096549A1 (en) Imidazopyridine-derivatives as inducible no-synthase inhibitors
AR047994A1 (es) Formas polimorficas de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidin-2,6-diona
PL361355A1 (en) Phenylglycine derivatives
PT1673370E (pt) Forma cristalina de linezolida
RS51541B (sr) 5-hloro-3-(4-metansulfonilfenil)-6'-metil-/2,3'/bipiridinil u čistom kristalnom obliku i postupak sinteze
HK1071059A1 (en) Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis
DE60216233D1 (en) Carbolinderivate
MY136824A (en) Substituted benzoxazinones and uses thereof
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
HK1096548A1 (en) Imidazopyridine-derivatives as inductible no-synthase inhibitors
HRP20030853B1 (en) Crystalline form of omeprazole
AU2001256344A1 (en) Novel solid body forms of mesoprogestin 11beta-[4e-(hydroxyiminomethyl)-phenyl]-17alpha-methoxymethy -17beta-methoxy-estra-4,9-dien-3-one
UA83266C2 (en) Oxazole derivatives of tetracyclines
SE9903290D0 (sv) Novel compounds
GB0229081D0 (en) Multifunctional cationic photoinitiators, their preparation and use
MXPA06003345A (es) Derivados de aminopiridina como inhibidores de la no-sintasa inducible.
MXPA03003971A (es) Derivados de indol como inhibidores de pde5.
GB0108903D0 (en) Novel crystalline forms of a factor Xa inhibitor
TW200500068A (en) Crystalline therapeutic agent
HUP0204422A3 (en) Calcium dicarboxylate ethers, methods of making the compounds, and pharmaceutical compositions containing them
IL158145A0 (en) Processes for preparing cycloheptapeptide compounds, novel cycloheptapeptide compounds and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20100427

Year of fee payment: 10

PBON Lapse due to non-payment of renewal fee

Effective date: 20110510